Zura Bio’s tibulizumab fails phase 2 trial for skin disease

🌐 Investing.com (Cyprus) —
Zura Bio’s tibulizumab fails phase 2 trial for skin disease

AI Summary

Zura Bio said its experimental drug tibulizumab failed to meet the required outcome in a phase 2 trial for a skin disease. The result is a setback for the company’s clinical-development program.

Markets Health Zura Bio tibulizumab phase 2 trial clinical trial failure skin disease biotechnology

Read original source →